DENTSPLY SIRONA (XRAY) Receives Daily Media Sentiment Score of 0.29
News headlines about DENTSPLY SIRONA (NASDAQ:XRAY) have been trending positive on Friday, Alpha One Sentiment Analysis reports. The research group, a division of Accern, identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real time. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. DENTSPLY SIRONA earned a media sentiment score of 0.29 on Alpha One’s scale. Alpha One also gave news articles about the medical instruments supplier an impact score of 32 out of 100, meaning that recent news coverage is unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news articles that may have effected Alpha One Sentiment’s rankings:
- Northcoast Research Brokers Lower Earnings Estimates for DENTSPLY SIRONA Inc (XRAY) (americanbankingnews.com)
- Home Healthcare HC Stocks in Focus=> DENTSPLY SIRONA Inc (NASDAQ:XRAY), Thermo Fisher Scientific Inc…. – usstockjournal (usstockjournal.com)
- Northcoast Research Weighs in on DENTSPLY SIRONA Inc’s Q3 2018 Earnings (XRAY) (americanbankingnews.com)
- The Q2 2017 EPS Estimates for DENTSPLY SIRONA Inc (XRAY) Decreased by Analyst – BangaloreWeekly (bangaloreweekly.com)
- The DENTSPLY SIRONA Inc (XRAY) Stake Boosted by Xact Kapitalforvaltning AB – BangaloreWeekly (bangaloreweekly.com)
A number of research firms have weighed in on XRAY. Zacks Investment Research raised shares of DENTSPLY SIRONA from a “sell” rating to a “hold” rating in a research report on Wednesday, April 19th. Barrington Research lowered shares of DENTSPLY SIRONA from an “outperform” rating to a “market perform” rating in a research report on Tuesday, February 21st. Jefferies Group LLC cut their target price on shares of DENTSPLY SIRONA from $70.00 to $68.00 and set a “buy” rating for the company in a research report on Monday, January 23rd. Finally, Stifel Nicolaus raised shares of DENTSPLY SIRONA from a “hold” rating to a “buy” rating and boosted their target price for the stock from $62.00 to $70.00 in a research report on Monday, February 13th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. DENTSPLY SIRONA currently has an average rating of “Buy” and a consensus price target of $68.11.
DENTSPLY SIRONA (NASDAQ:XRAY) traded down 0.71% on Friday, hitting $61.22. 202,140 shares of the stock traded hands. The firm’s 50 day moving average is $62.81 and its 200 day moving average is $60.59. DENTSPLY SIRONA has a 52 week low of $55.00 and a 52 week high of $65.83. The stock has a market cap of $14.03 billion, a price-to-earnings ratio of 39.40 and a beta of 1.21.
DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Tuesday, May 9th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by $0.01. The company had revenue of $900.50 million for the quarter, compared to analyst estimates of $916.55 million. DENTSPLY SIRONA had a return on equity of 8.04% and a net margin of 11.15%. The business’s quarterly revenue was up 16.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.69 EPS. Equities analysts anticipate that DENTSPLY SIRONA will post $2.84 earnings per share for the current year.
In other DENTSPLY SIRONA news, Director Eric Brandt sold 2,941 shares of DENTSPLY SIRONA stock in a transaction dated Thursday, March 2nd. The shares were sold at an average price of $64.35, for a total value of $189,253.35. Following the completion of the sale, the director now owns 4,722 shares in the company, valued at approximately $303,860.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Christopher T. Clark sold 89,700 shares of DENTSPLY SIRONA stock in a transaction dated Friday, April 7th. The stock was sold at an average price of $62.67, for a total transaction of $5,621,499.00. Following the completion of the sale, the chief executive officer now owns 112,067 shares of the company’s stock, valued at approximately $7,023,238.89. The disclosure for this sale can be found here. Insiders sold a total of 314,141 shares of company stock valued at $19,958,079 in the last quarter. Corporate insiders own 2.20% of the company’s stock.
TRADEMARK VIOLATION WARNING: “DENTSPLY SIRONA (XRAY) Receives Daily Media Sentiment Score of 0.29” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2017/05/19/dentsply-sirona-xray-receives-daily-media-sentiment-score-of-0-29.html.
About DENTSPLY SIRONA
DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.
Receive News & Stock Ratings for DENTSPLY SIRONA Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc and related stocks with our FREE daily email newsletter.